hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Temperature === Temperature is another interesting parameter to discuss since protein solubility is a function of temperature. In protein crystallization, manipulation of temperature to yield successful crystals is one common strategy. Unlike pH, temperature of different components of the crystallography experiments could impact the final results such as temperature of buffer preparation, temperature of the actual crystallization experiment, etc.
=== Murder conviction === Cochran was later convicted of first-degree murder in state court for poisoning her husband, Michael Brandon Cochran, with insulin. Prosecutors argued that Michael had grown suspicious of their business dealings and planned to investigate further. On February 5, 2019, Cochran canceled Michael’s flight to Virginia, where he intended to investigate their business dealings, and injected him with insulin. Despite his deteriorating condition, Cochran refused to take him to the hospital, telling friends he would “sleep it off.” Michael died on February 11, 2019. During the trial, forensic experts confirmed that Michael’s death was caused by nonprescribed insulin. Prosecutors argued that Cochran killed her husband to prevent him from uncovering her fraudulent activities. The jury deliberated for less than two hours before delivering a guilty verdict. In January 2025, Cochran was sentenced to life imprisonment without parole, with the jury recommending no mercy. After announcing in November 2023 that he would not run for re-election at the end of 2024, Judge H.L. Kirkpatrick, stated that he would preside over the Natalie Cochran trial by special appointment.
Specialized scalp tattoos can also mimic the appearance of a short buzzed haircut. Androgenic alopecia also occurs in women, and more often presents as diffuse thinning without hairline recession. Like its male counterpart, the condition rarely leads to total hair loss. Treatment options are similar to those for men, although topical or systemic estrogen is used more often.
== Clinical significance == Erectile dysfunction, the inability to achieve or maintain an erection, is the most common disorder of the penis, and most commonly results from vascular disease. Penile fracture is a rupture of the tunica albuginea caused by severe blunt trauma to the erect penis, which raises cavernosal pressure beyond what the tunica can withstand. Most cases occur during sexual intercourse. During erection the circular fibres of the tunica thin from around 2 mm to about 0.25 mm, and the weakest point lies on the ventral side of the shaft immediately adjacent to the urethra, where most ruptures occur; the urethra is involved in roughly 20% of cases. Buck's fascia normally confines the resulting haematoma and swelling to the penile shaft. Penile fracture is regarded as a urological surgical emergency, as delayed treatment can result in long-lasting sexual dysfunction. In Peyronie's disease, fibrous plaques containing excessive collagen form within the tunica albuginea, causing focal inelasticity and curvature of the penis. The condition is usually benign but may be associated with painful erections or erectile dysfunction. Its underlying pathogenesis is not known, although evidence suggests that repeated microtrauma leads to fibrin deposition from microvascular injury. Priapism is a prolonged, rigid erection occurring in the absence of appropriate stimulation, conventionally defined as one lasting four hours or longer and not relieved by ejaculation.
Water treatment is any process that improves the quality of water to make it appropriate for a specific end-use. The end use may be drinking, industrial water supply, irrigation, river flow maintenance, water recreation or many other uses, including being safely returned to the environment. Water treatment removes contaminants and undesirable components, or reduces their concentration so that the water becomes fit for its desired end-use. This treatment is crucial to human health and allows humans to benefit from both drinking and irrigation use. Advanced water treatment methods have been developed in recent decades due to increased concerns about new pollutants like microplastics, pharmaceuticals, and per- and polyfluoroalkyl substances (PFAS). These include advanced oxidation processes, membrane filtration, and adsorption-based techniques utilizing materials like tailored nanomaterials and activated carbon. Additionally, energy efficiency, resource recovery, and sustainability in water treatment systems are receiving more attention, especially in areas where water is scarce and environmental demands are growing.
Sources: en.wikipedia.org
== Stop codon recognition == The termination of translation is determined by the presence of a release factor recognizing a stop codon, which then catalyzes the release of the newly synthesized protein. There are three stop codon found within all domains of life: UGA, UAG, and UAA. Each stop codon starts with a uracil nucleotide followed by two purines (adenosine and guanine), which is essential for the molecular basis of stop codon recognition. The eRF1 protein is capable of recognizing all three stop codons, which means it must have a way to differentiate codons very efficiently. The three sites used for stop codon recognition are the YxxCxxxF, GTS loop and NIKS site. The main object of the highly specialized sites is to create extensive networks of hydrogen bonding crosslinking with the mRNA stop codon. The process is separated into two sections: recognizing the first nucleotide (uracil) and recognizing the second and third position nucleotides.
==== Cirkunovs v. Zuffa and Davis v. Zuffa ==== In May 2025, two antitrust lawsuits were filed against the UFC. One, led by former fighter Misha Cirkunov, specifically challenges the enforceability of arbitration clauses and class action waivers in UFC contracts. The other lawsuit, filed by former fighter Phil Davis, alleges that the UFC's anticompetitive practices also negatively impacted the ability of non-UFC fighters to secure fair wages.
==== Sweden ==== The Riksdag added 4-AcO-DMT to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of January 25, 2017, published by Medical Products Agency (MPA) in regulation HSLF-FS 2017:1 listed as "4-acetoxi-N,N-dimetyltryptamin".
=== Weaning === Weaning is the process of replacing breast milk with other foods; the infant is fully weaned after the replacement is complete. Psychological factors affect the weaning process for both mother and infant, as issues of closeness and separation are very prominent. Unless a medical emergency necessitates abruptly stopping breastfeeding, it is best to gradually increase the period between feedings or eliminate feedings to allow the breasts to adjust to the decreased demands without becoming engorged. Studies show that a large number of women discontinue breastfeeding early due to lack of working place support for breastfeeding mothers. La Leche League advises parents to shift their children's focus at bedtime away from breastfeeding, as it is often the most difficult feeding for them to let go. If weaning starts at 12 months or later, it is not necessary to switch to infant formula or "toddler formula" as is sold commercially. At 12 months, it is recommended that the baby be switched to whole cow's milk. Reduced-fat or skim milk generally is not appropriate before age 2 because it lacks sufficient fat or calories to promote early brain development. If the mother was experiencing lactational amenorrhea, periods will begin to return with weaning, along with restored fertility.
Arsenal financed moves for Granit Xhaka and Shkodran Mustafi in mid-2016 for a combined £65 million, rendering the pair one of Arsenal's most expensive ever signings, as Wenger hoped to guide the club to their first league title win in over thirteen years the following season. Although Arsenal began strongly in the league, losing only once until December, back-to-back defeats to Everton and Manchester City resulted in Arsenal losing their stronghold on the league. Wenger also served a four-match touchline ban and had to pay a £25,000 fine after pushing referee Anthony Taylor during a win at home against Burnley. Further defeats to Chelsea and Liverpool all but rendered Arsenal out of the title race, and left qualification to the Champions League threatened by March. On 30 April, Arsenal lost to main rivals Tottenham which had confirmed the latter had finished above them in the Premier League for the first time since the 1994–95 FA Premier League season. The following month also saw them fail to finish in the top four since the 1996–97 FA Premier League season. On 27 May, Wenger became the most successful manager in the history of the FA Cup as Arsenal beat Premier League winners Chelsea 2–1 at Wembley through goals from Alexis Sánchez and Aaron Ramsey. The victory represented a further record for Wenger, as Arsenal too, became the most successful club in the competition's history as they won the competition for the 13th time. Four days following the win, Wenger signed a contract extension until 2019.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.